ANIXA BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ANIXA BIOSCIENCES, INC. (ANIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.62 per share for the 12-month period ending 2025-10-31, per its 10-K filed 2026-01-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-01-12
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-07-31 was $3.09, a 50.56% decline year-over-year.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-04-30 was $0.24, a 14.29% decline year-over-year.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-01-31 was $0.09, a 47.06% decline year-over-year.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-07-31 was $6.25.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.62, a 44.90% decline from fiscal 2024.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $2.94, a 10.64% decline from fiscal 2023.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.29, a 50.92% increase from fiscal 2022.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.18, a 25.60% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-10-31 | $1.62 10-K · filed 2026-01-12 | |||||||
| 2024-10-31 | $2.94 10-K · filed 2026-01-12 | |||||||
| 2023-10-31 | $3.29 10-K · filed 2025-01-10 | |||||||
| 2022-10-31 | $2.18 10-K · filed 2024-01-16 | |||||||
| 2021-10-31 | $2.93 10-K · filed 2023-01-04 | |||||||
| 2020-10-31 | $2.97 10-K · filed 2022-01-04 | |||||||
| 2019-10-31 | $3.87 10-K · filed 2021-01-07 | |||||||
| 2018-10-31 | $3.31 10-K · filed 2020-01-09 | |||||||
| 2017-10-31 | $1.72 10-K · filed 2019-01-11 | |||||||
| 2016-10-31 | $2.84 10-K · filed 2018-01-09 | |||||||
| 2015-10-31 | $3.09 10-K · filed 2016-12-08 | |||||||
| 2015-07-31 | $3.09 10-Q · filed 2015-08-18 | $2.40 10-Q · filed 2015-08-18 | ||||||
| 2015-04-30 | $0.24 10-Q · filed 2015-05-22 | $0.09 10-Q · filed 2015-05-22 | ||||||
| 2015-01-31 | $0.09 10-Q · filed 2015-03-09 | |||||||
| 2014-10-31 | $5.75 10-K · filed 2015-12-23 | $0.23 10-K · filed 2015-01-29 | ||||||
| 2014-07-31 | $6.25 10-Q · filed 2015-08-18 | $0.25 10-Q · filed 2014-09-15 | $5.50 10-Q · filed 2015-08-18 | $0.22 10-Q · filed 2014-09-15 | ||||
| 2014-04-30 | $0.28 10-Q · filed 2014-06-16 | $0.17 10-Q · filed 2015-05-22 | $0.21 10-Q · filed 2014-06-16 | |||||
| 2014-01-31 | $0.17 10-Q · filed 2015-03-09 | |||||||
| 2013-10-31 | $0.17 10-K · filed 2015-01-29 | |||||||
| 2013-07-31 | $0.17 10-Q · filed 2014-09-15 | |||||||
| 2013-04-30 | $0.18 10-Q · filed 2014-06-16 | $0.17 10-Q · filed 2014-06-16 | ||||||
| 2013-01-31 | $0.17 10-Q · filed 2014-03-17 | |||||||
| 2012-10-31 | $0.18 10-K/A · filed 2014-01-17 | |||||||
| 2012-07-31 | $0.08 10-Q/A · filed 2013-09-20 | |||||||
| 2012-04-30 | $0.08 10-Q/A · filed 2013-06-19 | $0.08 10-Q/A · filed 2013-06-19 | ||||||
| 2012-01-31 | $0.08 10-Q/A · filed 2013-03-25 | |||||||
| 2011-10-31 | $0.15 10-K · filed 2013-01-29 | |||||||
| 2011-07-31 | $0.25 10-Q · filed 2012-09-14 | $0.16 10-Q · filed 2012-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |